
Overview
Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment.
Dr. Dezern is rated as an Experienced provider by MediFind in the treatment of Hemoglobinopathy. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration.
Her clinical research consists of co-authoring 225 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Hemoglobinopathy.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
The Johns Hopkins Hospital
Dr. Lydia H. Pecker is a pediatric hematologist and Director of the Young Adult Clinic at the Sickle Cell Center for Adults at Johns Hopkins. Dr. Pecker received her undergraduate degree in Africana studies from Brown University and earned her M.D. at the University of Pennsylvania School of Medicine. She completed residency training at Children’s Hospital at Montefiore and completed a fellowship at Children’s National Medical Center and the National Institutes of Health’s National Heart, Lung and Blood Institute before joining the Hopkins faculty in 2016. Dr. Pecker's NIH and foundation-funded research focuses on reproductive health in people with ovaries and sickle cell disease. Dr. Pecker is rated as a Distinguished provider by MediFind in the treatment of Hemoglobinopathy. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Tubal Ligation, and Bone Marrow Transplant.
Children's National Hospital
Robert Nickel is a Hematologist and an Oncologist in Washington, Washington, D.c.. Dr. Nickel has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Hemoglobinopathy. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant.
Rubenstein Child Health Building
"Dr. James Casella is a professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. As the Johns Hopkins’ Rainey Professor of Pediatric Hematology, Dr. Casella is chief of the Division of Pediatric Hematology at Johns Hopkins Children's and director of the Basic and Translational Research Program in Sickle Cell Disease, Comprehensive Sickle Cell Center and the Maryland Hemophilia Treatment Center at Johns Hopkins. He supervises several labs investigating the cellular and molecular basis of pediatric blood-borne diseases. He is seeking to develop better treatments for sickle cell disease and the prevention of central nervous system complications of this disorder, including stroke. Dr. Casella received his undergraduate degree in mathematics from Union College. He earned his M.D. from SUNY of Syracuse and completed a residency in pediatrics at Johns Hopkins University School of Medicine, where he was subsequently a fellow in hematology/oncology. He has been a member of the Johns Hopkins’ faculty since 1983. A research scientist as well as a clinician, he co-directs the hematology/oncology fellowship program at Johns Hopkins Hospital and is an adjunct senior investigator (Pediatric Oncology Branch) in the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health. He is also director of the NHLBI-funded K12 in benign hematology program at Johns Hopkins that trains young clinician/investigators in benign hematology and transfusion medicine. Dr. Casella has served on numerous university, hospital, and advisory committees, many geared toward hematology, pediatrics and transfusion. He has received many awards from the Johns Hopkins Hospital, including the Alexander ""Buck"" Schaffer Award for Outstanding Contribution to the Teaching of House Officers. He and a colleague created the Johns Hopkins/St. Agnes Comprehensive Hemophilia Clinic to improve care for patients with the disease.". Dr. Casella is rated as a Distinguished provider by MediFind in the treatment of Hemoglobinopathy. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Acute Myeloid Leukemia (AML)
- Aplastic AnemiaDr. Dezern isElite. Learn about Aplastic Anemia.
- Chronic Myelomonocytic Leukemia (CMML)
- Myelodysplastic Syndrome (MDS)
- Sideroblastic AnemiaDr. Dezern isElite. Learn about Sideroblastic Anemia.
- Distinguished
- Acute Myeloblastic Leukemia with MaturationDr. Dezern isDistinguished. Learn about Acute Myeloblastic Leukemia with Maturation.
- Acute Myeloblastic Leukemia without Maturation
- AnemiaDr. Dezern isDistinguished. Learn about Anemia.
- Ataxia-Pancytopenia SyndromeDr. Dezern isDistinguished. Learn about Ataxia-Pancytopenia Syndrome.
- Bone Marrow TransplantDr. Dezern isDistinguished. Learn about Bone Marrow Transplant.
- Childhood Acute Myeloid LeukemiaDr. Dezern isDistinguished. Learn about Childhood Acute Myeloid Leukemia.
- Advanced
- Acute Erythroid Leukemia (AEL)Dr. Dezern isAdvanced. Learn about Acute Erythroid Leukemia (AEL).
- Acute Lymphoblastic Leukemia (ALL)
- Acute Promyelocytic LeukemiaDr. Dezern isAdvanced. Learn about Acute Promyelocytic Leukemia.
- AgranulocytosisDr. Dezern isAdvanced. Learn about Agranulocytosis.
- Bone Marrow AspirationDr. Dezern isAdvanced. Learn about Bone Marrow Aspiration.
- Febrile NeutropeniaDr. Dezern isAdvanced. Learn about Febrile Neutropenia.
- Experienced
- Aleukemic Leukemia Cutis (ALC)Dr. Dezern isExperienced. Learn about Aleukemic Leukemia Cutis (ALC).
- Chronic Familial NeutropeniaDr. Dezern isExperienced. Learn about Chronic Familial Neutropenia.
- Chronic Myelogenous Leukemia (CML)Dr. Dezern isExperienced. Learn about Chronic Myelogenous Leukemia (CML).
- Diffuse Large B-Cell Lymphoma (DLBCL)Dr. Dezern isExperienced. Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
- HemoglobinopathyDr. Dezern isExperienced. Learn about Hemoglobinopathy.
- Hemolytic AnemiaDr. Dezern isExperienced. Learn about Hemolytic Anemia.

